Geode Capital Management LLC Sells 27,745 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM)

Geode Capital Management LLC trimmed its position in Contineum Therapeutics, Inc. (NASDAQ:CTNMFree Report) by 17.7% during the 3rd quarter, Holdings Channel.com reports. The firm owned 128,676 shares of the company’s stock after selling 27,745 shares during the period. Geode Capital Management LLC’s holdings in Contineum Therapeutics were worth $2,463,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp bought a new stake in shares of Contineum Therapeutics during the 2nd quarter valued at $356,000. Rhumbline Advisers bought a new position in shares of Contineum Therapeutics in the 2nd quarter worth about $118,000. Versant Venture Management LLC bought a new stake in Contineum Therapeutics during the second quarter worth about $16,169,000. Johnson & Johnson bought a new stake in Contineum Therapeutics during the second quarter worth about $34,853,000. Finally, Sandia Investment Management LP purchased a new stake in Contineum Therapeutics in the second quarter worth about $88,000.

Analyst Ratings Changes

A number of brokerages have recently commented on CTNM. Baird R W raised Contineum Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 22nd. Robert W. Baird assumed coverage on Contineum Therapeutics in a research note on Tuesday, October 22nd. They set an “outperform” rating and a $32.00 price objective for the company. Finally, Royal Bank of Canada cut their target price on Contineum Therapeutics from $32.00 to $31.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Contineum Therapeutics has a consensus rating of “Buy” and a consensus price target of $29.25.

View Our Latest Report on CTNM

Contineum Therapeutics Price Performance

Shares of CTNM opened at $13.77 on Wednesday. Contineum Therapeutics, Inc. has a twelve month low of $12.33 and a twelve month high of $22.00. The firm has a 50 day moving average of $15.29 and a 200 day moving average of $17.48.

Contineum Therapeutics (NASDAQ:CTNMGet Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.01. On average, equities research analysts predict that Contineum Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

About Contineum Therapeutics

(Free Report)

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).

See Also

Want to see what other hedge funds are holding CTNM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Contineum Therapeutics, Inc. (NASDAQ:CTNMFree Report).

Institutional Ownership by Quarter for Contineum Therapeutics (NASDAQ:CTNM)

Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.